Xenon Pharmaceuticals (XENE) FCF Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) posted quarterly FCF Margin of 822.6% for Q1 2025, up 96.47% quarter-over-quarter from 23324.24% in Q3 2022.

Xenon Pharmaceuticals (XENE) FCF Margin (2013 - 2025) Analysis & Trends

Xenon Pharmaceuticals (XENE) has reported FCF Margin for 10 consecutive years, with 822.6% the latest figure, recorded in Q1 2025.

In Q1 2025, FCF Margin changed N/A year-over-year to 822.6%; the TTM figure through Dec 2025 stood at 3732.23% (changed N/A YoY), while the FY2025 annual figure was 3732.23%, changed N/A from the prior year.
FCF Margin rose to 822.6% in Q1 2025 per XENE's latest filing, from 23324.24% in the prior quarter.
Across five years, FCF Margin topped out at 187.47% in Q3 2021 and bottomed at 23324.24% in Q3 2022.
Historically, FCF Margin has averaged 3684.8% across 3 years, with a median of 599.26% in 2021.
On a YoY basis, FCF Margin climbed as much as 27180 bps in 2022 and fell as far as 2313677 bps in 2022.
Xenon Pharmaceuticals' FCF Margin stood at 567.94% in 2021, then tumbled by 4007 bps to 23324.24% in 2022, then jumped by 96 bps to 822.6% in 2025.
Business Quant data shows XENE's FCF Margin at 822.6% in Q1 2025, 23324.24% in Q3 2022, and 3248.51% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Xenon Pharmaceuticals	6.03 Bn	6.03 Bn	-	-

Download Data